Newsroom

Veradermics Advances VDPHL01 in Phase 2/3 Clinical Trial for Female Pattern Hair Loss, Marking a Milestone in the Development of the Potential First-Ever Oral Prescription Treatment for Women

Veradermics Announces Oversubscribed $150 Million Series C Financing to Advance VDPHL01 Through Multiple Phase 3 Trials as Potentially the First Non-Hormonal Oral Therapeutic for Hair Regrowth in Women and Men

Veradermics Raises $75 Million in Series B Financing and Initiates Phase 2/3 Trial for Hair Loss

Veradermics CEO Reid Waldman is selected as a Forbes 30 Under 30 for 2024

Veradermics Doses First Patient in a First-in-Human Clinical Trial for VDPHL for the Treatment of Pattern Hair Loss (Androgenetic Alopecia)